1/65
Looks like no tags are added yet.
Nucleic acid inhibitor classes
Fluoroquinolones (DNA gyrase inhibitors), sulfonamides and potentiated sulfonamides (folic acid synthesis inhibitors), nitroimidazoles (toxic metabolite production), rifampin (inhibits DNA-dependent RNA polymerase); all work on nucleic acid synthesis via very different pathways
Fluoroquinolones labeled for dogs
Enrofloxacin (Baytril), marbofloxacin (Zeniquin), orbifloxacin (Orbax), difloxacin (Dicural)
Fluoroquinolones labeled for cats
Marbofloxacin, orbifloxacin, pradofloxacin (Veraflox)
Fluoroquinolones labeled for cattle
Enrofloxacin (Baytril 100), danofloxacin (Advocin), pradofloxacin (Pradalex)
Fluoroquinolones labeled for swine
Enrofloxacin (Baytril 100) and pradofloxacin (Pradalex)
Fluoroquinolones in poultry
Products were pulled from the market
Fluoroquinolones in horses
Used off-label: enrofloxacin, and occasionally marbofloxacin
Ciprofloxacin
Used off-label in dogs only (cheap); poorly absorbed in cats and really poorly absorbed in horses
Fluoroquinolone extralabel use
Prohibited in food animals
Fluoroquinolone mechanism of action
Inhibit DNA gyrase (topoisomerase II), required for bacterial DNA replication, transcription, repair, and recombination
Newer-generation fluoroquinolone mechanism
Also inhibit topoisomerase IV (pradofloxacin)
Fluoroquinolone activity
Bactericidal with a post-antibiotic effect
Fluoroquinolone spectrum
Gram-negative aerobes (enteric/BRDC) and staphylococci; similar to aminoglycosides but safer in azotemic patients (kidneys)
Fluoroquinolone activity against Pseudomonas
Some activity, use with caution; higher doses often needed (topical) and resistance can develop during treatment (especially enrofloxacin)
Other fluoroquinolone targets
Brucella, Legionella, Chlamydia, Leptospira, and sometimes Mycobacteria
Fluoroquinolone gaps
Poor against streptococci and not active against enterococci
Pradofloxacin spectrum
Best activity against anaerobes and better against gram-positive aerobes
Fluoroquinolone oral absorption
Well absorbed orally in monogastrics
Fluoroquinolone absorption exceptions
Ciprofloxacin is poorly absorbed in cats and horses; enrofloxacin is not given orally to kittens on a milk diet (chelation)
Fluoroquinolone distribution
Distribute well to tissues, penetrate well intracellularly and across barriers; enrofloxacin has the highest lipid solubility and volume of distribution
Enrofloxacin metabolism
Metabolized in vivo to the active metabolite ciprofloxacin (the only fluoroquinolone with this); species and age dependent
Enrofloxacin conversion to ciprofloxacin by species
41% cattle, 36% dogs, 17% horses, 0% foals, 16% kittens
Fluoroquinolone elimination
Mainly renal; exception is pradofloxacin (hepatic elimination)
Fluoroquinolone dosing interval
Moderate half-life; once daily due to the PAE (exception: twice daily ciprofloxacin in dogs)
Fluoroquinolone PK/PD
Concentration-dependent (concentration/time dependent); AUC24h:MIC ratio with a target of about 72 (higher than older guidelines)
Fluoroquinolone GI adverse effects
Rarely vomiting, diarrhea, abdominal pain in dogs and cats
Fluoroquinolone CNS toxicity
High doses or rapid IV administration cause CNS excitement, confusion, or seizures through inhibition of GABA; do not use in epileptic patients
Pradofloxacin adverse effect
Bone marrow suppression in dogs (and cats)
Ciprofloxacin in horses
Causes fatal colitis (PO or IV)
Fluoroquinolone cartilage toxicity
Severe; chelation of Mg++ in cartilage decreases chondrocyte adherence (possibly tendons and ligaments too)
Fluoroquinolone cartilage risk by age
Neonatal and young foals are most affected: young, large (35-80 kg), prey animals that run a lot, often sick (7-14 days of treatment); younger and heavier means more severe damage
Fluoroquinolone cartilage risk in other species
Any neonatal or young animal until cartilage is fully developed; concern with large and working breed dogs
Fluoroquinolone ocular toxicity in cats
Enrofloxacin is the main cause; dose dependent retinal degeneration and irreversible blindness (defective drug transporters)
Fluoroquinolone drug interactions
May inhibit clearance of some drugs (e.g., theophylline); chelation with antacids, sucralfate, and multivitamins (iron), so do not give orally at the same time
Fluoroquinolone resistance mechanisms
Alteration of the target enzyme (DNA gyrase) and reduced access through altered porins (Pseudomonas; resistance may develop during treatment, especially with enrofloxacin)
Fluoroquinolone key concepts
Broad spectrum (gram-negatives and staph), DNA gyrase inhibition and bactericidal, AUC:MIC, extralabel use prohibited in food animals, cartilage damage in the young (especially foals), retinal toxicity in cats (especially enrofloxacin), ciprofloxacin only for dogs
Sulfonamides approved for food animals
Sulfamethazine, sulfadimethoxine, sulfaquinoxaline, sulfachlorpyridazine (for testing, "sulfas are sulfas"; no need to memorize names)
Sulfonamide extralabel use
Prohibited in adult dairy cattle
Potentiated sulfonamide
A sulfonamide plus a dihydrofolate reductase inhibitor (DHFRI, a diaminopyrimidine)
Trimethoprim-sulfadiazine
Horses (and swine): Uniprim, Tucoprim, Equisul-SDT
Pyrimethamine-sulfamethoxazole
Horses for EPM: ReBalance
Ormetoprim-sulfadimethoxine
Dogs (and cats): Primor
Potentiated sulfonamides in companion animals
Used in companion animals and extralabel in swine
Sulfonamide and DHFRI activity alone
Each alone is bacteriostatic
Sulfonamide + DHFRI activity
Bactericidal (synergism, "potentiated")
Why use a sulfonamide alone
In ruminants, which do not absorb DHFRIs (it would just sit in the GI tract)
Sulfonamide mechanism of action
Inhibit dihydropteroate synthase, blocking conversion of PABA to dihydropteroic acid (folic acid synthesis)
DHFRI mechanism of action
Inhibit dihydrofolate reductase, blocking dihydrofolic acid to tetrahydrofolic acid; ultimately blocks thymidine synthesis (a component of DNA)
Why potentiated sulfonamides are safe for mammals
Mammals use dietary folate and do not require PABA; bacterial dihydrofolate reductase has 50,000-60,000 fold higher affinity for trimethoprim than mammalian DHFR
Potentiated sulfonamide spectrum
Broad spectrum covering all 4 quadrants; effective against protozoa; may work in some MRSA/MRSP; in vitro anaerobic susceptibility does not translate in vivo (not used clinically for anaerobes)
Potentiated sulfonamide uses
First-line for pyodermas, UTIs, and soft tissue infections if susceptible; one of the only safe oral options for horses (resistance is increasing, especially in horses)
Potentiated sulfonamide PK
Well absorbed orally; good tissue distribution (extracellular and intracellular); sulfadiazine and pyrimethamine best (including CNS and prostate); extensive hepatic metabolism; moderate half-life (once or twice daily); mainly renal elimination
Potentiated sulfonamide PK/PD
Time-dependent
Potentiated sulfonamide toxicity: horses
Minimal (occasional diarrhea); cheap
Potentiated sulfonamide toxicity: cats
Minimal; taste and difficulty pilling (slobbering)
Potentiated sulfonamide toxicity: ruminants and swine
Safe
Potentiated sulfonamide toxicity: dogs
The problem species; dogs lack N-acetyltransferase (detoxifying enzyme), so toxic metabolites are produced
Potentiated sulfonamide breed risks in dogs
Doberman Pinschers (hypersensitivity reactions, cytochrome b5 reductase), possibly Rottweilers; also Samoyeds and Miniature Schnauzers
Potentiated sulfonamide immune reactions in dogs
Polyarthropathy, polymyositis, lymphadenopathy, fever, glomerulonephropathy, focal retinitis, hemolytic anemia; typically reversible, idiosyncratic, onset 5-36 (mean 12) days; not really reported in other species
Potentiated sulfonamide cutaneous reactions in dogs
Range in severity and typically reversible (most common ADR in one study); includes Stevens-Johnson syndrome and toxic epidermal necrolysis (blistering and ulceration across the body, protein loss, can be fatal)
Potentiated sulfonamide hepatopathy and thrombocytopenia
Lower recovery rate; possibly dose-dependent ADR
Potentiated sulfonamide keratoconjunctivitis sicca
Possible toxic effect on the lacrimal gland, typically after prolonged administration (may occur after short periods); may not be reversible, so discontinue early; possible in horses
Potentiated sulfonamide hypothyroidism
Block formation of thyroxine and thyronine; reversible, usually disappears within 3 weeks of discontinuation; can affect thyroid hormone testing; avoid in animals already diagnosed as hypothyroid
Potentiated sulfonamide bone marrow suppression
Rare in any species; secondary to folate antagonism with long-term dosing; combining DHFRIs increases risk (e.g., EPM treatment with trimethoprim plus pyrimethamine)
Potentiated sulfonamide urinary crystals
Rare in any species; precipitation of sulfonamide in acidic urine (older formulations); ensure adequate hydration
Should we use TMS in dogs?
Yes, judiciously: 31 studies of 3,776 dogs showed mild adverse events in 2% and severe in 0.2%; 23 fewer adverse events per 1000 treated dogs than other antimicrobials; keratoconjunctivitis prevalence about 1.8% in 2,243 treated dogs